ASX-listed AVITA Medical jumps on positive trial result for vitiligo treatment

AVITA Medical

13/09/2022 02:13

** Shares of AVITA Medical Inc  AVH.AX  rise as much as
6.56% to A$1.950, highest since Aug 31
    ** Medical technology co achieves positive topline result in
a controlled trial (https://bit.ly/3dc1ua7)
    ** Controlled trial to evaluate the safety and effectiveness
of RECELL system, its treatment for repigmentation of stable
vitiligo lesions
    ** Says 36% of treatments resulted in repigmentation of at
least 80% of treated area
    ** Co continues to plan for submission to FDA by the end of
2022 
    ** Stock has fallen 46.5%, as of last close 

    

 (Reporting by Echha Jain in Bengaluru)
 ((Echha.jain@thomsonreuters.com))